-
By Lee I-chia / Staff reporter
Preliminary findings from a “mix-and-match” clinical trial of COVID-19 vaccines showed that people who received a first dose of the AstraZeneca vaccine and a second dose of the Moderna vaccine have higher antibody levels than those who received two doses of the AstraZeneca vaccine, Central Epidemic Command Center (CECC) specialist advisory panel convener Chang Shan-chwen (張上淳) said yesterday.
The clinical trial conducted by National Taiwan University (NTU) Hospital recruited 400 participants, who were divided into four groups of 100 people each, Chang, an NTU executive vice president, told reporters on the sidelines of the 10th TEPHINET Southeast Asia/Western Pacific Bi-Regional Scientific Conference in Taipei.
The first group was given two doses of the…
#vaccinepassport